About
About
About
EVIIVE is a Swiss biotech company pioneering the next generation of blood-based diagnostics through high-dimensional analysis of extracellular vesicles (EVs). Our mission is to unlock the immune system’s hidden signals to guide more precise, personalized treatment decisions — starting with immunotherapy in cancer.
At EVIIVE, we believe every patient deserves a biomarker that works for them.
At EVIIVE, we believe every patient deserves a biomarker that works for them.
At EVIIVE, we believe every patient deserves a biomarker that works for them.
Spun out from research at the University of Zurich, we’ve built a proprietary platform that profiles single EVs with exceptional resolution, revealing real-time immune dynamics that traditional biomarkers miss. Our technology is designed to work from just a small volume of plasma, enabling truly non-invasive diagnostics with clinical-grade performance.
We are a multidisciplinary team of scientists, clinicians, and entrepreneurs, working at the intersection of immunology, data science, and translational medicine. With strong academic roots, a growing IP portfolio, and partnerships across pharma and academia, we are rapidly advancing toward clinical implementation.
Leadership
Leadership
Leadership
Co-Founder & CEO
Molecular immunologist turned entrepreneur with deep EV diagnostics expertise. A former professional mountain biker, he now leads EVIIVE’s vision from bench to market—translating immune insights into investable, clinically meaningful diagnostics.
Co-Founder & CEO
Molecular immunologist turned entrepreneur with deep EV diagnostics expertise. A former professional mountain biker, he now leads EVIIVE’s vision from bench to market—translating immune insights into investable, clinically meaningful diagnostics.
Co-Founder & CEO
Molecular immunologist turned entrepreneur with deep EV diagnostics expertise. A former professional mountain biker, he now leads EVIIVE’s vision from bench to market—translating immune insights into investable, clinically meaningful diagnostics.
Co-Founder & CSO
Innovative molecular & cellular cancer immunologist, recently serving as Prof Dr at the University of Zurich. As scientific architect of EVIIVE’s cutting-edge diagnostic platform, he discovered key biomarkers & translated deep mechanistic insights into novel immuno-oncology diagnostics.
Co-Founder & CSO
Innovative molecular & cellular cancer immunologist, recently serving as Prof Dr at the University of Zurich. As scientific architect of EVIIVE’s cutting-edge diagnostic platform, he discovered key biomarkers & translated deep mechanistic insights into novel immuno-oncology diagnostics.
Co-Founder & CSO
Innovative molecular & cellular cancer immunologist, recently serving as Prof Dr at the University of Zurich. As scientific architect of EVIIVE’s cutting-edge diagnostic platform, he discovered key biomarkers & translated deep mechanistic insights into novel immuno-oncology diagnostics.
Clinical Advisor
Global leader in melanoma research and immunotherapy. Vice Chair of Dermatology at University Hospital Zurich, advising on clinical strategy, physician network development, and regulatory planning.
Clinical Advisor
Global leader in melanoma research and immunotherapy. Vice Chair of Dermatology at University Hospital Zurich, advising on clinical strategy, physician network development, and regulatory planning.
Clinical Advisor
Global leader in melanoma research and immunotherapy. Vice Chair of Dermatology at University Hospital Zurich, advising on clinical strategy, physician network development, and regulatory planning.
Scientific Advisor
Head of Pathology at University Hospital Zurich. Internationally recognized for cancer biomarker development and histopathological standards. Guides analytical validation, cohort design, and biomarker interpretation.
Scientific Advisor
Head of Pathology at University Hospital Zurich. Internationally recognized for cancer biomarker development and histopathological standards. Guides analytical validation, cohort design, and biomarker interpretation.
Scientific Advisor
Head of Pathology at University Hospital Zurich. Internationally recognized for cancer biomarker development and histopathological standards. Guides analytical validation, cohort design, and biomarker interpretation.
Commercial Advisor
Former SVP at Roche Diagnostics and General Manager at Abbott. Strategic advisor to ARCHIMED Investment Group. Brings 20+ years of global diagnostics leadership in Go-to-Market, partnerships, and exits.
Commercial Advisor
Former SVP at Roche Diagnostics and General Manager at Abbott. Strategic advisor to ARCHIMED Investment Group. Brings 20+ years of global diagnostics leadership in Go-to-Market, partnerships, and exits.
Commercial Advisor
Former SVP at Roche Diagnostics and General Manager at Abbott. Strategic advisor to ARCHIMED Investment Group. Brings 20+ years of global diagnostics leadership in Go-to-Market, partnerships, and exits.
Strategic & Commercial Advisor
Lars has 20 years of experience in the pharmaceutical and diagnostic industry. He held local and global leadership positions at Roche and AstraZeneca and has extensive experience in the commercialisation of drug-diagnostic combinations in oncology. Lars molecular biologist by training and obtained his PhD from the University of Cambridge.
Strategic & Commercial Advisor
Lars has 20 years of experience in the pharmaceutical and diagnostic industry. He held local and global leadership positions at Roche and AstraZeneca and has extensive experience in the commercialisation of drug-diagnostic combinations in oncology. Lars molecular biologist by training and obtained his PhD from the University of Cambridge.
Strategic & Commercial Advisor
Lars has 20 years of experience in the pharmaceutical and diagnostic industry. He held local and global leadership positions at Roche and AstraZeneca and has extensive experience in the commercialisation of drug-diagnostic combinations in oncology. Lars molecular biologist by training and obtained his PhD from the University of Cambridge.
Strategic & Commercial Advisor
30+ years of full-time Biopharma leadership including P&L responsibility with Pfizer/Wyeth, Novartis/Ciba, Bayer/Schering, MSD. Member of executive leadership teams at national and multi-national level with 11 resp. 54 countries. Worked and lived on Northern and Southern hemisphere as former serial intrapreneur in bringing multiple breakthroughs globally first to market. Business Angel and Board Member with BioValley Basel. Scientific background (BPharm) coupled with multiple executive leadership programs in US, EU, CH, RSA. Tri-lingual.
Strategic & Commercial Advisor
30+ years of full-time Biopharma leadership including P&L responsibility with Pfizer/Wyeth, Novartis/Ciba, Bayer/Schering, MSD. Member of executive leadership teams at national and multi-national level with 11 resp. 54 countries. Worked and lived on Northern and Southern hemisphere as former serial intrapreneur in bringing multiple breakthroughs globally first to market. Business Angel and Board Member with BioValley Basel. Scientific background (BPharm) coupled with multiple executive leadership programs in US, EU, CH, RSA. Tri-lingual.
Strategic & Commercial Advisor
30+ years of full-time Biopharma leadership including P&L responsibility with Pfizer/Wyeth, Novartis/Ciba, Bayer/Schering, MSD. Member of executive leadership teams at national and multi-national level with 11 resp. 54 countries. Worked and lived on Northern and Southern hemisphere as former serial intrapreneur in bringing multiple breakthroughs globally first to market. Business Angel and Board Member with BioValley Basel. Scientific background (BPharm) coupled with multiple executive leadership programs in US, EU, CH, RSA. Tri-lingual.
